Galimedix Therapeutics announced the initiation of its phase 2 eDREAM study to assess the safety and efficacy of GAL-101 eye drops in patients with dry age-related macular degeneration, according to a company press release.
“GAL-101 eye drops have already shown an excellent safety and tolerability profile in phase 1 clinical testing, and compelling efficacy with GAL-101 protecting neuronal retinal cells from toxic damage has been demonstrated in relevant ophthalmic preclinical models,” Hermann Russ, MD, PhD, co-founder and CSO of Galimedix, said in the release. “Despite